Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells
Antibody-conjugated nanoparticles (ACNPs), particularly immunoliposomes (ILs), have gained significant attention in cancer treatment due to their enhanced efficacy and superior tissue penetration. However, their high production costs and technical challenges underscore the need for more cost-effecti...
Saved in:
Main Authors: | Nilufer Cakir, Hatice Oncel, Aylin Ozkan, Dilan Bicak, Sibel Akgun Bas, Nur Mustafaoglu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-12-01
|
Series: | International Journal of Pharmaceutics: X |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590156725000520 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Adverse Effects and Use of Bevacizumab in Patients with Glioblastoma: A Systematic Review and Meta-Analysis
by: Alejandro Bruna-Mejías, et al.
Published: (2025-05-01) -
Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review
by: Oguz Ozel, et al.
Published: (2016-08-01) -
Development and Characterization of Optimized Drug-Loaded Niosomes for Delivery of 5-FU and Irinotecan
by: Kafilat O. Agbaje, et al.
Published: (2025-07-01) -
Evaluation of an innovative, green, and eco-friendly baclofen-loaded niosome (Baclosome) formulation for pain management by transdermal delivery
by: Jafar Akbari, et al.
Published: (2025-01-01) -
A glyco-engineering approach for site-specific conjugation to Fab glycans
by: Maria L. Jaramillo, et al.
Published: (2023-12-01)